METROPOLIS Metropolis Healthcare Q3 FY26 results (Oct–Dec 2025) and concall
Metropolis Healthcare delivered a strong Q3 FY26, with robust revenue growth across both group and organic segments, coupled with significant margin expansion for the organic business. The company announced a 3:1 bonus issue and reported progress on acquisitions, despite a one-time impact from Labor Code implementation and a delay in the genomics platform launch for Core Diagnostics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 136.4%, net profit up 35.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 11 | 4 | 23 | 23 | 26 +136% |
| EBITDA | 72 | 62 | 90 | 108 | 95 +32% |
| Net profit | 31 | 29 | 45 | 53 | 42 +35% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
